Application of CAR-T therapy in solid tumors: current opportunities and challenges
- 27 April 2026
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 33 (4) , 479-491
Abstract
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has achieved substantial progress in treating hematologic malignancies. However, its efficacy in solid tumors remains limited due to various biological and logistical challenges. This review systematically summarizes the advancements in CAR-T therapy for solid tumors, including lung cancer, pancreatic cancer, neuroblastoma, and breast cancer. It traces the progression of CAR-T cell design from the first to the fifth generation and explores the roles of key functional modules, such as scFv, hinge regions, and costimulatory domains. Major barriers to CAR-T application in solid tumors are discussed, including antigen heterogeneity, the lack of specific targets, CAR-T cell exhaustion, the immunosuppressive tumor microenvironment (TME), and physical barriers within tumor tissues. Additionally, the review highlights emerging strategies and recent developments from 2023 to 2025, such as bispecific and multispecific CAR-T cells, regional administration techniques, logic-gated CAR constructs, safety switches, and novel approaches to modulating the TME. Despite considerable challenges, the integration of these cutting-edge technologies is advancing CAR-T therapy for solid tumors, providing new prospects for patients with refractory solid malignancies. Finally, future directions for CAR-T applications in solid tumors are discussed.Keywords
This publication has 133 references indexed in Scilit:
- Engineering CAR‐T Therapeutics for Enhanced Solid Tumor TargetingAdvanced Materials, 2025
- CAR T cells in solid tumors and metastasis: paving the way forwardCancer and Metastasis Reviews, 2024
- Photo‐metallo‐immunotherapy: Fabricating Chromium‐Based Nanocomposites to Enhance CAR‐T Cell Infiltration and Cytotoxicity against Solid TumorsAdvanced Materials, 2024
- Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid TumorsAdvanced Functional Materials, 2024
- CAR-T Therapies in Solid Tumors: Opportunities and ChallengesCurrent Oncology Reports, 2023
- CAR T cell therapy in solid tumors: A review of current clinical trialseJHaem, 2021
- Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantationAmerican Journal of Hematology, 2021
- Delivery Techniques for Enhancing CAR T Cell Therapy against Solid TumorsAdvanced Functional Materials, 2021
- Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastomaCancer Immunology, Immunotherapy, 2021
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy, 2014